Abstract:EGFR T790 M accounts for 50% to 60% of cases of non-small-cell lung carcinoma (NSCLC) resistance to the first-generation EGFR tyrosine kinase inhibitors (TKIs). Hence, identifying novel compounds with activity against TKIs resistant is of great value. In this study, twenty honokiol and magnolol derivatives were isolated from the EtOH extract of Magnolia officinalis and the antiproliferative activity was evaluated on HCC827 (19del EGFR mutation), H1975 (L858 R/T790 M EGFR mutation), and H460 (KRAS mutation) cell lines. Among the isolated compounds, piperitylmagnolol (a 3-substituted magnolol derivative) showed the best antiproliferative activity against those three cell lines with the IC50 values of 15.85, 15.60 and 18.60 μM, respectively, which provided a direction for the structural modification of magnolol. Further structural modification led to the synthesis of thirty-one magnolol derivatives, and compounds A13, C1, and C2 exhibited significant and broad-spectrum antiproliferative activity with the IC50 values ranging from 4.81 to 13.54 μM, which were approximately 4- and 8-fold more potent than those of honokiol and magnolol, respectively. Moreover, their aqueous solubility was remarkably improved with 12-, 400- and 105 fold greater than those of honokiol and magnolol. Anti-tumor mechanism research revealed that these three compounds were able to induce cell cycle arrest at G0/G1 phase, cause efficient apoptosis in H1975 cells, and also prevent the migration of HUVECs in a dose-dependent manner through Cdk2, Cdk4, Cyclin E, and Cyclin D1 inhibition as well as up-regulation of cleaved-PARP and cleaved-caspase 3 levels. In in vivo antitumor activity, C2 (10, 30 and 100 mg/kg, po) dose-dependently inhibited the tumor growth in H1975 xenograft model with the tumor inhibition rate of 46.3%, 59.3% and 61.2% respectively, suggesting that C2 is a potential oral anticancer agent deserving further investigation.

Potent and Selective Inhibition of Magnolol on Catalytic Activities of Ugt1a7 and 1A9

Characterization of Hepatic and Intestinal Glucuronidation of Magnolol: Application of the Relative Activity Factor Approach to Decipher the Contributions of Multiple UDP-glucuronosyltransferase Isoforms.

Molecular Determinants of Magnolol Targeting Both RXRα and PPARγ

Magnolol and Luteolin Inhibition of α-Glucosidase Activity: Kinetics and Type of Interaction Detected by In Vitro and In Silico Studies

Probe Substrate and Enzyme Source-Dependent Inhibition of Udp-Glucuronosyltransferase (ugt) 1a9 by Wogonin

Selectivity for inhibition of nilotinib on the catalytic activity of human UDP-glucuronosyltransferases.

2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression

Potential interactions among myricetin and dietary flavonols through the inhibition of human UDP-glucuronosyltransferase in vitro

Glabrone As a Specific UGT1A9 Probe Substrate and Its Application in Discovering the Inhibitor Glycycoumarin.

Development of a UHPLC-MS/MS-based data-mining method for rapid profiling and characterization of magnolol metabolites in rat urine and plasma

Insights on the Multifunctional Activities of Magnolol

A Fluorescence-Based Microplate Assay for High-Throughput Screening and Evaluation of Human UGT Inhibitors.

Mechanistic insights of magnolol antimicrobial activity against Mycoplasma using untargeted metabolomic analyses

In vitro inhibitory activities of magnolol against Candida spp.

Deglycosylation of Liquiritin Strongly Enhances Its Inhibitory Potential Towards Udp-Glucuronosyltransferase (ugt) Isoforms

A broad-spectrum substrate for the human UDP-glucuronosyltransferases and its use for investigating glucuronidation inhibitors

Discovery and Synthesis of Novel Magnolol Derivatives with Potent Anticancer Activity in Non-Small Cell Lung Cancer.

Discovery and Characterization of the Key Constituents in Ginkgo biloba Leaf Extract With Potent Inhibitory Effects on Human UDP-Glucuronosyltransferase 1A1

Evaluation and Comparison of the Inhibition Effect of Astragaloside IV and Aglycone Cycloastragenol on Various UDP-Glucuronosyltransferase (UGT) Isoforms

Effects of Diammonium Glycyrrhizinate on Hepatic and Intestinal UDP-Glucuronosyltransferases in Rats: Implication in Herb-Drug Interactions.

Simultaneously Screening Multiple UGT1A1 Inhibitors from Polygonum Multiflorum Root Using Ultrafiltration LC-MS